Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Mumps Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Mumps Overview | 7 | 1 |
| Pipeline Products for Mumps Comparative Analysis | 8 | 1 |
| Mumps Therapeutics under Development by Companies | 9 | 1 |
| Mumps Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Mumps Pipeline Products Glance | 11 | 3 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Mumps Products under Development by Companies | 14 | 1 |
| Mumps Products under Investigation by Universities/Institutes | 15 | 1 |
| Mumps Companies Involved in Therapeutics Development | 16 | 8 |
| Beijing Minhai Biotechnology Co., Ltd | 16 | 1 |
| Beijing Tiantan Biological Products Co., Ltd. | 17 | 1 |
| China National Pharmaceutical Group Corporation | 18 | 1 |
| Daiichi Sankyo Company, Limited | 19 | 1 |
| GlaxoSmithKline Plc | 20 | 1 |
| Prometheon Pharma, LLC | 21 | 1 |
| Sinovac Biotech Ltd. | 22 | 1 |
| Zydus Cadila Healthcare Limited | 23 | 1 |
| Mumps Therapeutics Assessment | 24 | 6 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Combination Products | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 2 |
| Drug Profiles | 30 | 10 |
| (measles + mumps + rubella + varicella) (tetravalent) vaccine Drug Profile | 30 | 1 |
| (measles + mumps + rubella + varicella) vaccine Drug Profile | 31 | 1 |
| (measles + mumps + rubella) vaccine Drug Profile | 32 | 1 |
| (measles + mumps + rubella) vaccine Drug Profile | 33 | 1 |
| (measles + mumps + rubella) vaccine Drug Profile | 34 | 1 |
| (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine Drug Profile | 35 | 1 |
| measles + mumps + rubella + varicella vaccine Drug Profile | 36 | 1 |
| mumps vaccine Drug Profile | 37 | 1 |
| mumps vaccine Drug Profile | 38 | 1 |
| VN-0102 Drug Profile | 39 | 1 |
| Mumps Dormant Projects | 40 | 1 |
| Mumps Product Development Milestones | 41 | 2 |
| Featured News &Press Releases | 41 | 1 |
| Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus | 41 | 2 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |